Positron emission tomography in oncology

British Medical Bulletin

Volumn 79-80, Issue 1, 2006, Pages 171-186

  Berry, Jonathan D ^a   Cook, Gary J R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; HUMAN; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING;

HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547100530     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldl013     Document Type: Review

References (40)

1. Rankin SC (2003) Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging, 30 (Suppl 1), pS56-S64.
2. Erasmus JJ, Gladish GW, Broemeling L et al. (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol, 21, 2574-2582.
3. Nutt R (2002) 1999 ICP Distinguished Scientist Award. The history of positron emission tomography. Mol Imaging Biol, 4, 11-26.
4. von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology, 238, 405-422.
5. Hoekstra CJ, Paglianiti I, Hoekstra OS et al. (2000) Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med, 27, 731-743.
6. Keyes JWJ (1995) SUV: standard uptake or silly useless value. J Nucl Med, 36, 1836-1839.
7. Zasadny KR, Wahl RL (1993) Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology, 189, 847-850.
8. Sokoloff L (1981) The deoxyglucose method: theory and practice. Eur Neurol, 20, 137-145.
9. Warburg O (1956) On the origin of cancer cells. Science, 123, 307-339.
10. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst, 97, 172-187.
11. Schmid DT, John H, Zweifel R et al. (2005) Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology, 235, 623-628.
12. Cook GJ, Wegner EA, Fogelman I (2004) Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med, 34, 122-133.
13. Cook GJ, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med, 26, 308-314.
14. Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med, 26, 1363-1378.
15. Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics, 19, p61-77, quiz 150-151
16. Lewis PJ, Salama A (1994) Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med, 35, 1647-1649.
17. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med, 23, 1409-1415.
18. Reinhardt MJ, Wiethoelter N, Matthies A et al. (2006) PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging, 33, 134-139.
19. Antoch G, Freudenberg LS, Egelhof T et al. (2002) Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med, 43, 1339-1342.
20. Armstrong P, Congleton DJ, Fountain SW et al. (2001 ) Guidelines on the selection of patients with lung cancer for surgery. British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. Thorax, 56, 89-108
21. Lardinois D, Weder W, Hany TF et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med, 348, 2500-2507. (Pubitemid 36706537)
22. Lowe VJ, Naunheim KS (1998) Positron emission tomography in lung cancer. Ann Thorac Surg, 65, 1821-1829.
23. Keidar Z, Haim N, Guralnik L et al. (2004) PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med, 45, 1640-1646.
24. Wang ZJ, Reddy GP, Gotway MB et al. (2004) Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics, 24, 105-119.
25. Abdel-Nabi H, Doerr RJ, Lamonica DM et al. (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology, 206, 755-760.
26. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M (2003) Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med, 44, 1784-1788.
27. Cohade C, Osman M, Leal J, Wahl RL (2003) Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 44, 1797-1803.
28. Goerres GW, Stupp R, Barghouth G et al. (2005) The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 32, 153-162.
29. Moog F, Bangerter M, Diederichs CG et al. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 203, 795-800.
30. Schaefer NG, Hany TF, Taverna C et al. (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT. Radiology, 232, 823-829.
31. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA (2005) FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics, 25, 191-207.
32. Kitagawa Y, Nishizawa S, Sano K et al. (2003) Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med, 44, 198-206.
33. Branstetter BFt, Blodgett TM, Zimmer LA et al. (2005) Head and neck malignancy: is PET/ CT more accurate than PET or CT alone. Radiology, 235, 580-586.
34. Weir L, Worsley D, Bernstein V (2005) The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J, 11, 204-209.
35. Kalra MK, Maher MM, Mueller PR, Saini S (2003) State-of-the-art imaging of pancreatic neoplasms. Br J Radiol, 76, 857-865.
36. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K (2003) PET in the follow-up of differentiated thyroid cancer. Br J Radiol, 76, 690-695.
37. Grisaru D, Almog B, Levine C et al. (2004) The diagnostic accuracy of 18Ffluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol, 94, 680-684.
38. Grigsby PW, Siegel BA, Dehdashti F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol, 19, 3745-3749.
39. Kumar R, Alavi A (2005) Clinical applications of fluorodeoxyglucose- positron emission tomography in the management of malignant melanoma. Curr Opin Oncol, 17, 154-159.
40. Gutzeit A, Antoch G, Kuhl H et al. (2005) Unknown primary tumors: detection with dualmodality PET/CT-initial experience. Radiology, 234, 227-234.